Ventromedial Hypothalamic Lesions and the Mobilization of Fatty Acids

YOSHIKI NISHIZAWA and GEORGE A. BRAY, Department of Medicine, University of California, Los Angeles School of Medicine, Harbor General Hospital Campus, Torrance, California 90509

ABSTRACT We have explored the effects of ventromedial hypothalamic lesions on the mobilization of free fatty acids in rats exposed to several stresses. The rise in free fatty acids and glycerol in response to norepinephrine had the same time-course and dose-response characteristics in the sham-operated and lesioned animals, indicating comparable degrees of peripheral responsiveness to this hormone. Forced swimming significantly lowered insulin and increased glycerol and free fatty acids more in control than in ventromedial hypothalamic-lesioned rats. During fasting, the rise in glycerol and free fatty acids was smaller in the lesioned rats, but the fall in insulin was greater. Exposure to cold raised fatty acids and glycerol more in the control than in the sham-operated animals, but had no significant effect on plasma insulin or glucose concentration. Injection of 2-deoxyglucose was done on lesioned or control rats with intact or removed adrenal medullas. The rise in free fatty acids and glycerol was less in the lesioned rats than in the controls, and was not affected by adrenomedullation. The rise in glucose, however, was completely blocked in the adrenomedullated rats. Changes in insulin were small and not statistically significant. The reduced mobilization of fatty acids from adipose tissue depots after ventromedial hypothalamic injury is consistent with the hypothesis that the ventromedial hypothalamic region serves to modulate activation of the sympathetic nervous system.

INTRODUCTION

Several experimental models of obesity have been used in the search for increased understanding of the syndromes of human obesity. These models include the obesity that is genetically transmitted (1, 2), the obesity that follows dietary manipulations (3), the obesity that results from alterations in endocrine function (2), and obese animals with bilateral ventromedial hypothalamic lesions (4).

This latter syndrome of hypothalamic obesity results from destruction of the ventromedial region of the hypothalamus in both man (5) and animals (4). The pathologic lesions that have been associated with this syndrome in human beings include tumors, inflammatory lesions, trauma, and congenital malformations (5). Like its experimental counterpart, this syndrome in man is associated with an initial period of weight gain followed by a plateau in body weight. Most of the increase in body weight can be accounted for by an increase in the size of pre-existing fat cells (5). Hyperphagia, hypometabolism, and abnormalities of endocrine function are frequent features of both the human and experimental syndromes (4, 5).

The region of the hypothalamus whose injury produces this syndrome sits astride the fibers of the sympathetic nervous system (6–8) and, thus, suggests the possibility that it may modulate the function of the adrenergic nervous system. Diminished activity of the sympathetic nervous system might be involved in the hyperinsulinemia characteristic of this syndrome in both animals and man (4, 5). Reduced sympathetic activity might also account for the lower concentrations of glucagon and the smaller salivary glands that have been reported to follow ventromedial hypothalamic injury and obesity in experimental animals (9). The present experiments were designed to examine the effects of ventromedial hypothalamic injury in experimental animals using mobilization of fatty acids from adipose tissue as an index of activation of the sympathetic nervous system.

METHODS

Animals

The 336 female Wistar rats used for these studies were obtained from Simonsen Laboratories, Gilroy, Calif., and weighed between 240 and 280 g. They were fed pelleted or

Received for publication 7 February 1977 and in revised form 26 October 1977.

The Journal of Clinical Investigation  Volume 61  March 1978:714-721
group which were fed as described above underwent the final swim for 60 min, after which they were sacrificed.

Cold exposure. Rats were placed in individual stainless steel cages in a cold room at 4°C for 60 min before autopsy. They had been fed up until the time of cold exposure. Each group consisted of seven or eight rats.

Fasting. Food was removed at 8 a.m. from three groups containing eight sham-operated and three groups with a similar number of VMH-lesioned rats. One group with each type of operation was killed when the food was removed; a second pair of groups at 4 p.m.; and the third pair of groups at 8 a.m. the next day.

2-Deoxy-D-glucose. 2-Deoxy-D-glucose (Sigma Chemical Co., St. Louis, Mo.), was dissolved in distilled water and administered intraperitoneally at a dose of 500 mg/kg. Both the adrenomedullated and sham-demmedullated rats had been fed until the time of treatment. They were sacrificed 30 min later. Each vehicle or treatment group contained 10 rats.

Norepinephrine. 1-Norepinephrine (Winthrop Laboratories, Evanston, Ill.) was dissolved in 0.15 M sodium chloride solution and administered intraperitoneally in doses of 30, 100, 300, and 600 μg/kg and for the time-course experiment, in doses of 100 μg/kg. Each treatment group for the time-course contained 8 rats, whereas the dose-response study contained 10 rats in each group.

Assays

Serum glucose was measured by the glucose oxidase method which also measures 2-deoxy-D-glucose (Glucose Analyzer; Beckman Instruments, Inc., Fullerton, Calif.). The addition of 2-deoxy-D-glucose at a concentration of 100 μg increased the apparent concentration of glucose by 40 mg/dl. Serum free fatty acids (FFA) were assayed by the method of Dole (13) using 0.5-ml aliquots of serum. Serum glycerol was determined by the glycerol kinase method of Davidson and Karjala (14). Immunoreactive insulin was determined by a double antibody method using rat insulin standards and iodinated pork insulin with an anti-insulin antibody raised in the guinea pig (15).

Statistical treatment

The data were analyzed by analysis of variance, and results are expressed as the mean±SEM. Statistical significance was selected at a level of P < 0.05.

RESULTS

Experiment 1

Time-course of response to norepinephrine. A dose of norepinephrine of 100 μg/kg body weight significantly increased the serum glycerol and FFA in both lesioned and control rats killed 10, 15, and 30 min after injection (F = 3.35; P = 0.026 for rise in FFA) (Fig. 2), but there were no significant differences between the groups (P = 0.067). Indeed, glycerol rose more and FFA somewhat less in the VMH-lesioned rats. Glucose also rose after injection of norepinephrine (135±2 to 213±10 mg/dl in controls and 135±4 to 229±11 mg/dl in VMH-lesioned rats), but there were no significant differences between the two groups at any time. Immunoreactive insulin was significantly higher in

---

**Note:**

1. Abbreviation used in this paper: VMH, ventromedial hypothalamic.
The rise rats differences the variance, concentration of and 30 after no was insulin between rats). The rise in glycerol was slightly more and the rise in FFA was slightly less in the VMH-lesioned rats, but there were no significant differences by analysis of variance.

VMH-lesioned rats (38.5±7 vs. 21.2±3.4 μU/ml), and decreased after injection of norepinephrine (minimum of 6.6±2.0 in control and 11.9±3.9 μU/ml in VMH-lesioned rats). The difference in immunoreactive insulin between the two groups had disappeared at 15 and 30 min after injecting norepinephrine.

Experiment 2

Dose response to norepinephrine. A rise in the concentration of glycerol and FFA was observed with all doses of norepinephrine (Fig. 3). By analysis of variance, the rise in FFA was significantly higher in the sham-operated controls ($F = 8.24; P = 0.006$), but there was no significant difference in the two groups in the rise of glycerol after norepinephrine. Glucose increased similarly in the VMH-lesioned and intact animals after injection of norepinephrine (135±3 to 280±53 mg/dl in controls and 133±4 to 274±5 mg/dl in VMH-lesioned rats). Immunoreactive insulin was higher in the VMH-lesioned groups (63.5±14 vs. 20.5±4.4 μU/ml) and decreased in both groups. Significant differences were still present after 30, 100, and 300 μg/kg but not at 600 μg/kg of norepinephrine.

Experiment 3

Exercise. FFA and glycerol concentrations were the same in the groups of animals that did not exercise. FFA were significantly higher in the control rats which swam for 60 min when compared to the VMH-lesioned animals which had exercised for the same period of time (Fig. 4). Glycerol concentrations behaved similarly (0.21±0.03 and 0.20±0.01 μmol/ml in control and 0.59±0.04 and 0.47±0.05 μmol/ml after exercise in control and VMH-lesioned groups, respectively). Glucose also increased in rats that had exercised (177±6 mg/dl in control and 175±8 mg/dl in VMH-lesioned animals), but there were no differences in glucose concentration in those animals that exercised and those that did not (141±4 mg/dl in control and 135±10 mg/dl in VMH-lesioned rats). The concentrations of insulin were higher in the VMH-lesioned rats that did not exercise (31.5±7.0 vs. 16.6±4.3 μU/ml). The values in the groups that exercised were lower (2.1±0.9 μU/ml in control and 7.5±0.9 μU/ml in VMH-lesioned rats) and significantly different.

Experiment 4

Exposure to cold. FFA were significantly higher in the animals exposed to cold than in the animals that were not cold stressed (Table I). After exposure to cold, the VMH-lesioned animals had significantly lower concentrations of FFA (515±30 vs. 626±24 μeq/ml) and glycerol (0.29±0.01 vs. 0.37±0.018 μmol/ml) than did the sham-operated animals. Glucose decreased slightly but there was no difference between the lesioned and sham-operated animals (137±3 before, to 126±4 mg/dl after cold in control and 135±3 before, to 121±1 mg/dl after cold in VMH-lesioned rats). The concentration of insulin was higher in the VMH-lesioned animals (47.9±13 vs. 24.3±2 μU/ml), and there was no significant change in insulin after 60 min of exposure to the cold (22.5±3.2 μU/ml in control and 46.7±6.9 μU/ml in VMH-lesioned rats).

Experiment 5

Fasting. FFA and glycerol rose after 8 and 24 h of fasting and were significantly higher in the fasted sham-operated animals than in the VMH-lesioned
animals (Table II). Glucose decreased significantly during the first 7 h of fasting but was not significantly different between the two groups at the beginning or end of the fast. The concentration of immunoreactive insulin fell with fasting but remained significantly higher in the VMH-lesioned rats at each time than at the corresponding times for the sham-operated animals (Table II).

Experiment 6

2-Deoxy-d-glucose. FFA rose more in the control animals treated with 2-deoxy-d-glucose than in the VMH-lesioned rats treated similarly (Table III). Adrenomedullation did not modify the effect of 2-deoxy-d-glucose on FFA, but partially blocked the increase in serum glucose. Indeed, the apparent increase of 23 mg/dl in measured glucose could be accounted for by a 2-deoxy-d-glucose concentration of 50 mg/dl. The levels of immunoreactive insulin were significantly higher in the lesioned rats, but there were no changes after injecting 2-deoxy-d-glucose in the adrenomedullated rats. In contrast, there was a slight decrease in insulin the sham-operated adrenomedullated animals injected with 2-deoxy-d-glucose.

DISCUSSION

The present experiments have examined the effects of VMH lesions on the mobilization of FFA by rats exposed to a variety of stresses. To interpret these experiments, it is essential to know that the response to exogenous norepinephrine was similar in VMH-lesioned and in sham-operated controls. The first two

| TABLE I  |
| Effects of Exposure to Cold on VMH and Sham-Operated Rats |

<table>
<thead>
<tr>
<th></th>
<th>VMH-lesioned rats</th>
<th>Sham-operated rats</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No cold</td>
<td>Cold</td>
</tr>
<tr>
<td>No. of animals</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Body weight</td>
<td>294±4†</td>
<td>290±3</td>
</tr>
<tr>
<td>Glucose, mg/dl</td>
<td>135±6</td>
<td>121±1</td>
</tr>
<tr>
<td>FFA, μeq/liter</td>
<td>401±41</td>
<td>515±30</td>
</tr>
<tr>
<td>Glycerol, μmol/ml</td>
<td>0.24±0.02</td>
<td>0.29±0.01</td>
</tr>
<tr>
<td>Immunoreactive insulin, μU/ml</td>
<td>47.9±13.2</td>
<td>46.7±6.9</td>
</tr>
</tbody>
</table>

* Comparison of no cold vs. cold.
† Mean±SEM for eight VMH-lesioned or seven sham-operated rats per group.
experiments were designed to make this comparison by measuring the time-course and dose response to exogenous norepinephrine. The rise in glycerol as a measure of lipolysis was the same (dose-response curve) or greater (time-course) in the VMH-lesioned animals than in controls. Both the log-dose response to the injection of norepinephrine and the time-course of response showed a smaller rise in FFA than glycerol in the lesioned rats. This smaller rise in FFA relative to glycerol suggests the possibility that reesterification was occurring more rapidly in the adipose tissue of the lesioned animals. Inasmuch as reesterification requires a continuous supply of glycerol-3-phosphate generated from glycerol, this result might be expected if the higher levels of insulin were biologically active. The smaller rise in FFA relative to glycerol might also reflect differences in the rate of peripheral removal of these two substances. The available data indicate that removal of both glycerol and FFA is a linear function of their plasma concentration (16, 17). It seems unlikely, therefore, that the parallel rise in glycerol and FFA can reflect anything but enhanced lipolysis under the conditions of these experiments. This implies that the myriad of factors that might have modified the response to exogenous norepinephrine did not affect the model used here. We were particularly concerned with the possibility that the hyperinsulinemia that characterizes the VMH-lesioned syndrome (4, 5) might interfere with

### Table II

**Effects of Fasting on VMH and Sham-Operated Rats**

<table>
<thead>
<tr>
<th></th>
<th>VMH-lesioned rats</th>
<th>Sham-operated rats</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 h</td>
<td>8 h</td>
<td>24 h</td>
</tr>
<tr>
<td>No. of animals</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Body weight</td>
<td>244±4</td>
<td>245±3</td>
<td>244±4</td>
</tr>
<tr>
<td>Glucose, mg/dl</td>
<td>136±3</td>
<td>126±2</td>
<td>108±2</td>
</tr>
<tr>
<td>P§</td>
<td>&lt;0.05</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>FFA, μeq/liter</td>
<td>366±50</td>
<td>631±51</td>
<td>916±26</td>
</tr>
<tr>
<td>P§</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Glycerol, μmol/ml</td>
<td>0.20±0.02</td>
<td>0.32±0.02</td>
<td>0.33±0.02</td>
</tr>
<tr>
<td>P§</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Immunoreactive insulin, μU/ml</td>
<td>59.8±4.8</td>
<td>17.7±2.4</td>
<td>15.2±4.7</td>
</tr>
<tr>
<td>P§</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td></td>
</tr>
</tbody>
</table>

* Comparison of values between VMH-lesioned and sham-operated animals after 24 h of fasting.
† Mean±SEM for eight animals.
§ Comparison of 8 and 24 h of fasting with fed animals.

### Table III

**Effect of 2-Deoxy-D-Glucose in Intact and Adrenomedullated Rats with Sham-Operations or VMH-Lesions**

<table>
<thead>
<tr>
<th></th>
<th>Sham lesions</th>
<th>VMH lesions</th>
<th>P1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenomedullation</td>
<td>0</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>2-Deoxy-D-glucose, 560 mg/kg</td>
<td>0</td>
<td>+</td>
<td>0</td>
</tr>
<tr>
<td>Body weight, g</td>
<td>266±4</td>
<td>269±4</td>
<td>269±4</td>
</tr>
<tr>
<td>Glucose, mg/dl</td>
<td>144±4</td>
<td>269±20</td>
<td>140±2</td>
</tr>
<tr>
<td>P§</td>
<td>&lt;0.001</td>
<td>&lt;0.05</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FFA, μeq/liter</td>
<td>355±20</td>
<td>606±77</td>
<td>309±28</td>
</tr>
<tr>
<td>P§</td>
<td>&lt;0.05</td>
<td>&lt;0.01</td>
<td>NS</td>
</tr>
<tr>
<td>Glycerol, μmol/ml</td>
<td>0.19±0.01</td>
<td>0.26±0.01</td>
<td>0.21±0.02</td>
</tr>
<tr>
<td>P§</td>
<td>&lt;0.01</td>
<td>&lt;0.05</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Immunoreactive insulin, μU/ml</td>
<td>30.4±2.8</td>
<td>22.6±2.1</td>
<td>20.3±3.0</td>
</tr>
<tr>
<td>P§</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>

* Rats were adrenomedullated 8 wk before the hypothalamic lesions.
† Comparison of 2-deoxy-D-glucose treated animals in sham-operated and VMH-lesioned groups.
§ Mean±SEM for 10 animals per group.
§ Effect of treatment with 2-deoxy-D-glucose.
The lipolytic effect of norepinephrine, because insulin is an antilipolytic agent for catecholamine-induced lipolysis (18). Hyperinsulinemia was present in the VMH-lesioned rats in all experiments even though body weights and food intake were similar to those in the sham-operated animals. This confirms data from other laboratories (19–21). An effect of the higher insulin levels on metabolism of adipose tissue may be reflected in the lower concentrations of FFA relative to glycerol in the first two experiments. The fact that the rise in glycerol was greater than the rise in FFA in response to log-dose increases in norepinephrine indicates, however, that the hyperinsulinemia of the VMH-lesioned rats was not inhibiting catecholamine-induced lipolysis in vivo. In the remaining studies, we have, therefore, used the changes in the serum concentrations of FFA and glycerol as an index of the response to endogenous norepinephrine released from the sympathetic nervous system.

Differences in the initial concentrations of glycerol and FFA between VMH-lesioned and intact rats would also have influenced the interpretation of our experiments. To select the most appropriate model, we compared the effect of stress in both ad lib. and pair-fed lesioned rats. When VMH-lesioned rats were allowed to eat ad lib., the concentrations of FFA and glycerol were significantly lower. Pair-feeding for the latter half of the experiment (Fig. 1), however, produced animals with the same final body weight and similar concentrations of glycerol and FFA. We thus used pair-fed animals for the remaining studies.

With all of the stressful experimental manipulations employed in this study, the rise of FFA and glycerol was significantly less in the VMH-lesioned animals than in the sham-operated controls. This supports the concept that the VMH lesion interferes with mobilization of FFA during stress in the experimental syndrome of hypothalamic obesity. A similar conclusion has been suggested previously by Inoue et al. (9). In this earlier study, it was observed that VMH lesions were associated with a rise in insulin, a decline in serum glucagon, and a decrease in the weight of the submandibular salivary glands. These findings were interpreted to indicate decreased sympathetic activity after VMH injury. The present studies strengthen this hypothesis.

Physical exertion mobilized FFA, increased glucose, and significantly decreased insulin in both VMH-lesioned and sham-operated animals. A rise in FFA and glucose and a fall in insulin have been noted previously by others (22–27). Luyckx et al. (28) showed that immunosympathectomy significantly reduced the rise in FFA and that adrenomedullation did not affect it, indicating the importance of the sympathetic nervous system in the mobilization of fatty acids during exercise. Our studies are consistent with this interpretation and show, in addition, that the magnitude of the response in the VMH-lesioned animals is smaller than in the intact controls.

The effect of cold exposure was different in two respects from that of forced exercise. Although the rise in FFA in the VMH-lesioned animals was significantly less than in the controls, neither glucose nor insulin changed during 60 min in the cold. This implies that the magnitude of cold exposure as a stress was less than that of forced exercise or, alternatively, that the mobilization of FFA in the cold was due to release of epinephrine from the adrenal medulla. Maickel et al. (29) have examined this latter possibility and found that removal of the adrenal medulla does not diminish the mobilization of FFA. We would thus conclude that cold was a less severe "stress" than forced exercise, and that it is modified by VMH-lesions.

Fasting is known to increase the concentration of FFA (29–32), and this is consistent with our findings. In addition to raising FFA, fasting also increased glycerol and reduced both insulin and glucose in all groups, but the effects were greater in the sham-operated animals than in those with VMH lesions.

The experiment with 2-deoxy-D-glucose is consistent with the observations of others (33, 34). The rise in FFA was significantly less than in the VMH-lesioned animals whether the adrenal medulla was present or not, implying that catecholamines from the adrenal medulla are not involved in this effect. Others have shown, however, that more extensive hypothalamic lesions, such as deafferentation, completely block the rise of FFA (33). The rise in glucose, on the other hand, was abolished in the lesioned and intact animals in the absence of the adrenal medulla. This has been emphasized by previous studies showing loss of the hyperglycemic response to 2-deoxy-D-glucose in the absence of the adrenal medulla (34, 35). The VMH lesions per se, however, did not affect the rise in glucose. This suggests that the hyperglycemia and the mobilization of lipid are controlled by separate regions of the hypothalamus which act through different peripheral mechanisms.

The present experiments tested the hypothesis that VMH lesions might interfere with adrenergic control of FFA mobilization. They are consistent with this hypothesis and suggest that the ventromedial hypothalamus may modulate lipid storage and release in man (4) and animals (5). Modulation of lipid mobilization could have profound effects on storage of body fat. It has long been known that bilateral lesions of the ventromedial hypothalamus result in obesity (4, 5, 36, 37). Our understanding of the organization of the ventromedial hypothalamus has been extended by the anatomic observations of Ban (6, 7) and by the studies with electrical stimulation published by Frohman and Bernardis (38) and by Shimazu and his colleagues.
(39–41). Ban (6, 7) has shown that the VMH nucleus is part of the anatomic organization of the sympathetic neural output from the hypothalamus. He divides the hypothalamus into medial and lateral parasympathetic zones separated by a medial sympathetic zone. The ventromedial region of the hypothalamus lies in this medial sympathetic zone. Stimulation of this region raises glucose and glucagon, and decreases insulin during the period of stimulation. It also raises growth hormone (42). Shimazu et al. (39–41) found an increase in glucose and have shown that stimulation of the ventromedial region of the hypothalamus can activate hepatic enzymes involved in glycogenolysis and gluconeogenesis. Electrical stimulation of this region in the rabbit brain can also increase lipolysis (41). Our studies have extended this concept by showing that destruction of the ventromedial sympathetic region of the hypothalamus is followed by a reduction in the mobilization in FFA by stimuli that involve the sympathetic nervous system. These studies taken together suggest that the ventromedial hypothalamus may act as a modulator of peripheral efferent adrenergic activity, particularly that involved with regulating adipose tissue mass.

Reduced activity of the sympathetic nervous system would also be expected to increase the concentration of insulin, to decrease the concentration of glucagon, and to reduce lipolysis, all of which have been observed in the syndrome of hypothalamic obesity (9). Such a sequence of events would favor the storage of triglycerides and thus the development of obesity. These observations of decreased sympathetic activity in the experimental animals provide a basis for reevaluating those patients who have the syndrome of hypothalamic obesity and suggest that sympathomimetic agents may be of value in treatment of these individuals.

ACKNOWLEDGMENTS

The technical help of Ms. M. Lee and the secretarial help of Ms. J. Martinez are gratefully acknowledged.

This work was supported in part by National Institutes of Health grants AM 15165 and AM 18186.

REFERENCES


